Clinical trials: Treatment Resistant Depression (TRD)
Major Depressive Disorder, Treatment-Resistant Depression
Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients
In this double-blind, randomized, sham-controlled trial, the investigators aimed to examine the effect of accelerated piTBS on suicide risk in a group of treatment-resistant patients with MDD (i.e., TRD), using an extensive…
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Suicide Ideations
- Trial name
- NCT06372834
- Testing
- piTBS being delivered using the Magstim Rapid2 stimulator
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Major Depressive Disorder
Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study
number of center : 1 duration of study : 24 months recruitement time : 23 months Aim :Principal Evaluate the interest of maintenance rTMS in a one-year double blind randomized controlled study for TRD patients.
- Trial name
- TMS/DEP (NCT02383693)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Major Depressive Disorder, Bipolar Disorder
Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)
Background: People with TRD are often helped by electroconvulsive therapy (ECT). But ECT can affect memory and thinking. Researchers want to study a treatment called TEST that uses less electricity.
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
- Trial name
- NCT05172271
- Testing
- MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD)
Cannabidiol Oil for Treatment-Resistant Major Depression
Major depressive disorder is one of the leading causes of disability worldwide, and a substantial proportion of patients do not achieve adequate improvement with conventional antidepressant treatments.
- Trial name
- ANANDA (NCT07696871)
- Testing
- Full-spectrum CBD oil 100 mg/mL
- Where
- Brazil
- Volunteers
- 120 people
- Sponsor
- Universidade do Sul de Santa Catarina
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- aTBS (NCT03068715)
- Testing
- Active TBS-DLPFC, Open label TBS-DLPFC
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Treatment Resistant Depression (TRD)
Treatment Resistant Depression and Vagus Nerve Stimulation
Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments.
- Trial name
- DepVNS (NCT05952674)
- Testing
- Vagus Nerve Stimulation (VNS), Best Medical Treatment
- Where
- 24 sites in France
- Volunteers
- 166 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Moderate Depression, Major Depressive Disorder
Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique
The aim of this study is to explore the effectiveness and safety of different doses of neural regulation under the guidance of pBFS technology in improving symptoms in patients with moderate to severe depressive disorders.
- Conditions
- Moderate Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT06112652
- Testing
- 4 session rTMS, 6 session rTMS, 8 session rTMS
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changping Laboratory
Major Depressive Disorder
Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)
An open label study to assess the safety, tolerability, and effects of intranasal Ketamine in combination with rTMS for patients with treatment-resistant major depressive disorder (TRD).
- Trial name
- NCT04352621
- Testing
- intranasal ketamine, rTMS treatment
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Treatment-Resistant Depression, Treatment-resistant Depression (TRD)
Focused Ultrasound Neuromodulation in Patients With Treatment-Resistant Depression
The goal of this clinical trial is to evaluate the safety and initial effectiveness of Magnetic Resonance-guided focused ultrasound neuromodulation using the Next Generation Dome Helmet (NGDH) device in patients with…
- Trial name
- NCT07094789
- Testing
- Next Generation Dome Helmet (NGDH)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Sunnybrook Health Sciences Centre
Depression and Quality of Life, Treatment Resistant Depression (TRD)
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression
This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings.
- Conditions
- Depression and Quality of Life, Treatment Resistant Depression (TRD), Anhedonia, Apathy
- Trial name
- ESKPSY (NCT07146503)
- Testing
- Esketamine (Intranasal Spray)
- Where
- 5 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Riccardo Guglielmo
Treatment Resistant Depression (TRD)
Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing
Ketamine is a medicine used in psychiatry for treatment-resistant depression. This study compares two ways of framing ketamine treatment: a psychedelic framing and a biomedical framing.
- Trial name
- KetSet (NCT07824973)
- Testing
- Psychedelic framing, Biomedical framing
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Valdemar Landgren
Treatment Resistant Depression (TRD)
Algorithm Guided Treatment Versus Treatment as Usual (TAU) for Patients With Treatment Resistant Depression
The trial utilizes a pragmatic, randomized, open label design with two parallel arms. Participants aged 18-65 with a diagnosis of unipolar depressive disorder and without stable remission in the past 12 months are randomized 1:1…
- Trial name
- NCT07080723
- Testing
- Algorithm guided treatment (AGT), Treatment as usual (TAU)
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Aalborg University Hospital
Depression
A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)
This is a multi-site, double-blind, placebo-controlled study of the acute efficacy of brexpiprazole or placebo in combination with intranasal ketamine added to ongoing, stable, and adequate antidepressant therapy (ADT) in the…
- Trial name
- NCT03149991
- Testing
- Brexpiprazole, Ketamine
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Biomarker-Guided Antidepressant Selection
Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments.
- Conditions
- Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine
- Trial name
- BioSelect (NCT07680140)
- Testing
- TMS, Ketamine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Weill Medical College of Cornell University
Treatment-resistant Depression (TRD)
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Psilocybin-assisted psychotherapy requires a lot of resources, with more psychotherapy being provided to integrate the meanings and insights derived from the psilocybin dosing sessions.
- Trial name
- PSI-GROUP (NCT07737990)
- Testing
- Group integration therapy
- Where
- Canada
- Volunteers
- 65 people
- Sponsor
- Joshua Rosenblat
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Ketogenic Diet and Neuromodulation in Treatment Resistant Depression
The goal of this clinical trial is to learn if combining a ketogenic diet with a personalized, accelerated brain stimulation treatment (iTBS) works better than iTBS with a standard healthy diet to reduce depression symptoms in…
- Trial name
- ALIGN (NCT07376018)
- Testing
- Accelerated Intermittent Theta Burst Stimulation (iTBS), Ketogenic Diet, Canadian Food Guide-Aligned Diet
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Optimization of IV Ketamine for Treatment Resistant Depression
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD.
- Trial name
- NCT00768430
- Testing
- Ketamine, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people
- Sponsor
- Baylor College of Medicine
Depression
Intranasal Ketamine in Ultra-REsistant Depression (SURE-ECT Non Responders)
Despite the known efficacy of pharmacotherapy (i.e. antidepressants) and psychotherapeutic interventions in treating depressive disorders, research evidence suggests that 20% to 40% of patients with major depressive disorder…
- Trial name
- SURE-ECT (NCT05137938)
- Testing
- Intranasal Ketamine (IN)
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale…
- Trial name
- RECOVER (NCT03887715)
- Testing
- Vagus Nerve Stimulation (VNS)
- Where
- 101 sites in United States
- Volunteers
- 6,800 people
- Sponsor
- LivaNova
Treatment Resistant Major Depressive Disorder
Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study
The purpose of this study is to determine if any improvements in depressive symptoms are maintained in the medium and longer-term (up to 3 months)
- Trial name
- ZYL-730-02 (NCT05438758)
- Testing
- Almond Therapy, Intranasal ketamine (Esketamine), Treatment as Usual
- Sponsor
- Zylorion Health